Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.09 USD | +1.72% | -3.14% | -14.06% |
Apr. 01 | Titan Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Jan. 26 | Titan Pharmaceuticals Regains Compliance With Nasdaq Listing Rule | MT |
Business Summary
Number of employees: 4
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Pharmaceutical Products
100.0
%
| 1 | 100.0 % | 0 | 100.0 % | -66.97% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 1 | 100.0 % | 0 | 100.0 % | -66.97% |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Avraham Ben-Tzvi
BRD | Director/Board Member | 53 | 22-08-14 |
Gim Shen Seow
CEO | Chief Executive Officer | 42 | 23-10-11 |
Brynner Chiam
BRD | Director/Board Member | - | 23-10-11 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 914,234 | 498,544 ( 54.53 %) | 0 | 54.53 % |
Stock B | 0 | 950,000 | 0 | 0 |
Company contact information
Titan Pharmaceuticals, Inc.
400 Oyster Point Boulevard Suite 505
94080-1958, South San Francisco
+650 244 4990
http://www.titanpharm.comSector
1st Jan change | Capi. | |
---|---|---|
-14.06% | 6.48M | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- TTNP Stock
- Company Titan Pharmaceuticals, Inc.